Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the…
Atrial fibrillation (AF) is an abnormal heart rhythm characterized by rapid and irregular beats of the atrial chambers of the heart. AF is the most common arrhythmia treated in clinical practice…
The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…
The demand for safe and effective obesity drugs is increasing due to the rising prevalence of obesity and the growing interest in incretin therapies, whose efficacy is approaching that of bariatric…
Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. It typically develops in early childhood and can persist into adulthood. The…
Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. The primary goal of CD treatment is to induce and…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…
The hemophilia A treatment landscape has evolved with the acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment. Offering improved treatment outcomes, Hemlibra…
Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive…
The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…
Immune checkpoint inhibitors have revolutionized the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to advanced disease, the anti-PD-1…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…
The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…